Xeris Biopharma Holdings, Inc.

Total Valuation

Xeris Biopharma Holdings, Inc. carries a market capitalization of 1.52B, placing it among publicly traded companies globally. Its enterprise value stands at 1.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Xeris Biopharma Holdings, Inc. currently has 172.56M shares outstanding.

Valuation Ratios

Xeris Biopharma Holdings, Inc. trades at a trailing price-to-earnings ratio of 79.65. The price-to-sales ratio is 3.04, and the price-to-book ratio stands at -1.43.

Enterprise Valuation

On an enterprise value basis, Xeris Biopharma Holdings, Inc. trades at an EV/EBITDA multiple of 22.67 and an EV/FCF ratio of 14.29. The EV/Sales ratio of 3.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.73 provides insight into valuation relative to core operating earnings.

Financial Position

Xeris Biopharma Holdings, Inc. maintains a current ratio of 2.12, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,987.19, indicating moderate leverage, while an interest coverage ratio of 1.70 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Xeris Biopharma Holdings, Inc.'s stock has gained approximately 70.81712% over the past 52 weeks. The 50-day moving average sits at 7.08, while the 200-day moving average is 7.07.

Income Statement

Over the trailing twelve months, Xeris Biopharma Holdings, Inc. generated 314.85M in revenue and converted that into 12.01M in net income, yielding earnings per share of 0.07. EBITDA reached 48.66M, while operating income came in at 35.90M.

Balance Sheet

Xeris Biopharma Holdings, Inc. holds 111.75M in cash and equivalents against 258.55M in total debt, resulting in a net debt position of 109.47M. Total book value stands at -669.05M, with working capital of 133.09M providing operational flexibility.

Cash Flow

Xeris Biopharma Holdings, Inc. produced 48.53M in operating cash flow over the past twelve months.

Margins

Xeris Biopharma Holdings, Inc. operates with a gross margin of 85.89, reflecting its pricing power and cost economics. The operating margin of 11.40 and net profit margin of 3.81 provide insight into operational efficiency.

Dividends & Yields

Scores

Xeris Biopharma Holdings, Inc. posts an Altman Z-Score of 0.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.